DNB Asset Management AS Increases Holdings in CVS Health Corporation $CVS

DNB Asset Management AS lifted its stake in CVS Health Corporation (NYSE:CVS) by 66.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 379,890 shares of the pharmacy operator’s stock after purchasing an additional 151,934 shares during the quarter. DNB Asset Management AS’s holdings in CVS Health were worth $28,640,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its stake in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after buying an additional 142 shares during the last quarter. Corundum Trust Company INC purchased a new position in CVS Health during the 3rd quarter valued at $29,000. Front Row Advisors LLC grew its position in CVS Health by 436.5% in the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after acquiring an additional 371 shares during the last quarter. SOA Wealth Advisors LLC. increased its stake in CVS Health by 36.9% in the third quarter. SOA Wealth Advisors LLC. now owns 486 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 131 shares during the period. Finally, Twin Peaks Wealth Advisors LLC bought a new stake in shares of CVS Health during the second quarter worth $36,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Price Performance

Shares of CVS stock opened at $79.74 on Friday. The stock’s 50-day moving average is $78.39 and its 200 day moving average is $77.13. CVS Health Corporation has a 1-year low of $58.35 and a 1-year high of $85.15. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. The company has a market cap of $101.44 billion, a P/E ratio of 57.78, a PEG ratio of 0.81 and a beta of 0.50.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating the consensus estimate of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period in the prior year, the firm posted $1.19 earnings per share. The company’s quarterly revenue was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health’s payout ratio is currently 192.75%.

Analyst Upgrades and Downgrades

CVS has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of CVS Health from $93.00 to $101.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Argus dropped their target price on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, January 28th. UBS Group reaffirmed an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Barclays boosted their price target on CVS Health from $87.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, Mizuho raised their price objective on CVS Health from $88.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Nineteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and a consensus price target of $94.91.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.